THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net
S U M M A R Y
DIARY: October 2, 2008 08:30 AM Thursday;
Rod Welch
Millie 3rd treatment 8th cycle cetuximab Carboplatin 4th relapse IBC.
1...Summary/Objective
...Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
...Cetuxiab Alone Clinical Study
...Cetuxiab 31 and Carboplatin 19 Treatments Clinical Study 2nd Arm
2...Schedule Weekly Treatments Continue on Thursdays
3...Labs Blood Test
4...NEUTS 1.93 Increase 2nd Week Chemotherapy Received
5...Chemotherapy Received Blood Counts Rise Significantly
6...Blood Counts Rise Significantly Chemotherapy Carboplatin Received
7...Neupogen Case Study Missed Carboplatin Treatments Low Blood Counts
8...Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
..............
Click here to comment!
CONTACTS
SUBJECTS
Cetuximab Carboplatin Clinical Study 2nd Arm 7th Cycle 1st Treatment
1003 -
1003 - ..
1004 - Summary/Objective
1005 -
100501 - Follow up ref SDS H4 0000. ref SDS H1 0000.
100502 -
100503 -
100504 -
100505 -
100506 -
100508 - ..
1006 -
1007 -
1008 - Progress
1009 -
100901 - Background on Millie's treatment in the clinical study is reported on
100902 - 080508. ref SDS A0 TZ8I
100904 - ..
100905 - Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
100906 -
100907 - Follow up ref SDS H4 X33O, ref SDS H1 X33O.
100908 -
100909 - Millie had left mastectomy on 051021. Biopsy at that time reported
100910 - no findings of cancer. Approximately 8 months later on 060707 the
100911 - doctor diagnosed IBC relapse and prescribed treatment with
100912 - capecitabine and Taxotere, which had been effective in 2005
100913 - completely eliminating signs of IBC disease. ref SDS 5 PF3O
100914 -
100915 - 1. Cycle 09 and 01 ................... 060721, ref SDS 6 407N
100916 - 2. Cycle 10 and 02 ................... 060814, ref SDS 8 LY6O
100917 - 3. Cycle 11 and 03 ................... 060908, ref SDS 8 407N
100918 - 4. Cycle 12 and 04 ................... 060929, ref SDS 8 407N
100919 - 5. Cycle 13 and 05 ................... 061020, ref SDS 9 407N
100920 - 6. Cycle 14 and 06 ................... 061110, ref SDS 10 407N
100921 - 7. Cycle 15 and 07 ................... 061201, ref SDS 11 407N
100923 - ..
100924 - Cetuxiab Alone Clinical Study
100925 -
100926 - Follow up ref SDS H4 356I, ref SDS H1 356I.
100927 -
100928 - After 7 cycles of treatment in 2006, the doctor diagnosed IBC
100929 - disease was progressing, and so made referral to UCSF for referral
100930 - in clinical study of Cetuximab and Carboplatin. Millie was
100931 - randominzed for treatment with Cetuximab alone, and began weekly
100932 - treatments at UCSF on 080201.
100934 - ..
100935 - Total Cetuximab
100936 - 8. Cycle 01 and 08 and 01 01.......... 070201, ref SDS 13 SG8I
100937 - 9. Cycle 01 and 08 and 02 02.......... 070208, ref SDS 14 SG8I
100938 - 10. Cycle 01 and 08 and 03 03.......... 070215, ref SDS 15 SG8I
100939 - 11. Cycle 01 and 08 and 04 04.......... 070222, ref SDS 16 SG8I
100940 - 12. Cycle 02 and 09 and 01 05.......... 070301, ref SDS 18 SG8I
100941 - 13. Cycle 02 and 09 and 02 06.......... 070308, ref SDS 20 7T3H
100942 - 14. Cycle 02 and 09 and 03 07.......... 070315, ref SDS 21 7T3H
100943 - 15. Cycle 02 and 09 and 04 08.......... 070322, ref SDS 22 7T3H
100944 - 16. Cycle 03 and 10 and 01 09.......... 070329, ref SDS 23 7T3H
100945 - 17. Cycle 03 and 10 and 02 10.......... 070405, ref SDS 24 7T3H
100946 - 18. Cycle 03 and 10 and 03 11.......... 070412, ref SDS 25 7T3H
100947 - 19. Cycle 03 and 10 and 04 12.......... 070419, ref SDS 26 7T3H
100948 - 20. Cycle 04 and 11 and 01 13.......... 070426, ref SDS 27 7T3H
100949 - 21. Cycle 04 and 11 and 02 14.......... 070503, ref SDS 28 7T3H
100950 - 22. Cycle 04 and 11 and 03 15.......... 070510, ref SDS 29 7T3H
100951 - 23. Cycle 04 and 11 and 04 16.......... 070517, ref SDS 30 7T3H
100952 - 24. Cycle 05 and 12 and 01 17.......... 070524, ref SDS 31 7T3H
100953 - 25. Cycle 05 and 12 and 02 18.......... 070531, ref SDS 32 7T3H
100954 - 26. Cycle 05 and 12 and 03 19.......... 070607, ref SDS 33 7T3H
100955 - 27. Cycle 05 and 12 and 04 20.......... 070614, ref SDS 34 0001
100956 - 28. Cycle 06 and 13 and 01 21.......... 070621, ref SDS 35 0001
100957 - 29. Cycle 06 and 13 and 02 22.......... 070628, ref SDS 36 0001
100958 - 30. Cycle 06 and 13 and 03 23.......... 070705, ref SDS 37 0001
100959 - 31. Cycle 06 and 13 and 04 24.......... 070712, ref SDS 37 0001
100960 - 32. Cycle 07 and 14 and 01 25.......... 070719, ref SDS 38 0001
100961 - 33. Cycle 07 and 14 and 02 26.......... 070726, ref SDS 36 0001
100962 - 34. Cycle 07 and 14 and 03 27.......... 070802, ref SDS 37 0001
100963 - 35. Cycle 07 and 14 and 04 28.......... 070809, ref SDS 39 0001
100964 - 36. Cycle 08 and 15 and 01 29.......... 070816, ref SDS 40 0001
100965 - 37. Cycle 08 and 15 and 02 30.......... 070823, ref SDS 41 0001
100966 - 38. Cycle 08 and 15 and 03 31.......... 070830, ref SDS 41 0001
100967 - 39. Cycle 08 and 15 and 04 32.......... 070906, ref SDS 42 0001
100968 - 40. Cycle 09 and 16 and 01 33.......... 070920, ref SDS 43 0001
100969 - 41. Cycle 09 and 16 and 02 34.......... 070927, ref SDS 44 0001
100970 - 42. Cycle 09 and 16 and 03 35.......... 071004, ref SDS 45 0001
100971 - 43. Cycle 09 and 16 and 04 36.......... 071011, ref SDS 46 0001
100972 - 44. Cycle 10 and 17 and 01 37.......... 071018, ref SDS 47 0001
100973 - 45. Cycle 10 and 17 and 02 38.......... 071025, ref SDS 48 0001
100974 - 46. Cycle 10 and 17 and 03 39.......... 071101, ref SDS 34 0001
100975 - 47. Cycle 10 and 17 and 04 40.......... 071108, ref SDS 49 0001
100976 - 48. Cycle 11 and 18 and 01 41.......... 071115, ref SDS 50 0001
100977 - 49. Cycle 11 and 18 and 02 42.......... 071122, ref SDS 36 0001
100978 - 50. Cycle 11 and 18 and 03 43.......... 071129, ref SDS 53 0001
100979 - 51. Cycle 11 and 18 and 04 44.......... 071206, ref SDS 54 0001
100980 - 52. Cycle 12 and 19 and 01 45.......... 071213, ref SDS 57 0001
100981 - 53. Cycle 12 and 19 and 02 46.......... 071220, ref SDS 60 0001
100982 - 54. Cycle 12 and 19 and 03 47.......... 071227, ref SDS 61 0001
100983 - 55. Cycle 12 and 19 and 04 48.......... 080103, ref SDS 62 0001
100984 - 56. Cycle 13 and 20 and 01 49.......... 080110, ref SDS 65 0001
100985 - 57. Cycle 13 and 20 and 02 50.......... 080117, ref SDS 66 0001
100986 - 58. Cycle 13 and 20 and 03 51.......... 080124, ref SDS 67 0001
100987 - 59. Cycle 13 and 20 and 04 52.......... 080131, ref SDS 69 0001
100988 - 60. Cycle 14 and 21 and 01 53.......... 080207, ref SDS 73 0001
100989 - 61. Cycle 14 and 21 and 02 54.......... 080214, ref SDS 74 0001
100990 - 62. Cycle 14 and 21 and 03 55.......... 080221, ref SDS 37 0001
100991 - 63. Cycle 14 and 21 and 04 56.......... 080228, ref SDS 79 0001
100992 - 64. Cycle 15 and 22 and 01 57 01 00... 080306, ref SDS 82 TZ8I
100994 - ..
100995 - Cetuxiab 31 and Carboplatin 19 Treatments Clinical Study 2nd Arm
100996 -
100997 - Follow up ref SDS H4 5B6J, ref SDS H1 5B6J.
100998 -
100999 - On 080207 doctor reports IBC may be spreading. ref SDS 72 GH5H
101000 - Follow up examination on 080219 Doctor Rugo diagnosed progression of
101001 - disease. ref SDS 94 3J4I Photographs show spread of IBC rash, UCSF
101002 - prescribed treatment under the 2nd Arm of the study so that Millie
101003 - now gets weekly treatment with cetuximab and with Carboplatin 3
101004 - weeks of each 4 week cycle.
101005 -
101006 - 2nd
101007 - Arm Cetuximab Carboplatin
101008 - 65. Cycle 01 15 and 22 and 02 58 02 01... 080313, ref SDS 84 TZ8I
101009 - 66. Cycle 01 15 and 22 and 03 59 03 01... 080320, ref SDS 85 TZ8I
101010 - 67. Cycle 01 15 and 22 and 04 60 04 01... 080327, ref SDS 86 TZ8I
101011 - 68. Cycle 02 16 and 23 and 01 61 05 02... 080403, ref SDS 87 TZ8I
101012 - 69. Cycle 02 16 and 23 and 02 62 06 03... 080410, ref SDS 90 TZ8I
101013 - 70. Cycle 02 16 and 23 and 03 63 07 03... 080417, ref SDS 92 TZ8I
101014 - 71. Cycle 02 16 and 23 and 04 64 08 03... 080424, ref SDS 95 TZ8I
101015 - 72. Cycle 03 17 and 24 and 01 65 09 04... 080501, ref SDS 98 5B6J
101016 - 73. Cycle 03 17 and 24 and 02 66 10 05... 080508, ref SDS A0 5B6J
101017 - 74. Cycle 03 17 and 24 and 03 67 11 05... 080515, ref SDS A1 5B6J
101018 - 75. Cycle 03 17 and 24 and 04 68 12 05... 080522, ref SDS A2 5B6J
101019 - 76. Cycle 04 18 and 25 and 01 69 13 06... 080529, ref SDS A5 5B6J
101020 - 77. Cycle 04 18 and 25 and 02 70 14 07... 080605, ref SDS A6 5B6J
101021 - 78. Cycle 04 18 and 25 and 03 71 15 08... 080612, ref SDS A9 5B6J
101022 - 79. Cycle 04 18 and 25 and 04 72 16 08... 080619, ref SDS B2 5B6J
101023 - 80. Cycle 05 19 and 26 and 01 73 17 09... 080626, ref SDS B7 5B6J
101024 - 81. Cycle 05 19 and 26 and 02 74 18 10... 080703, ref SDS C2 5B6J
101025 - 82. Cycle 05 19 and 26 and 03 75 19 11... 080710, ref SDS C5 5B6J
101026 - 83. Cycle 05 19 and 26 and 04 76 20 11... 080717, ref SDS D1 5B6J
101027 - 84. Cycle 06 20 and 27 and 01 77 21 12... 080724, ref SDS D8 5B6J
101028 - 85. Cycle 06 20 and 27 and 02 78 22 13... 080731, ref SDS E2 5B6J
101029 - 86. Cycle 06 20 and 27 and 03 79 23 14... 080807, ref SDS E8 5B6J
101030 - 87. Cycle 06 20 and 27 and 04 80 24 14... 080814, ref SDS F4 5B6J
101031 - 88. Cycle 07 21 and 28 and 01 81 25 14... 080821, ref SDS F6 5B6J
101032 - 89. Cycle 07 21 and 28 and 02 82 26 15... 080828, ref SDS G4 5B6J
101033 - 90. Cycle 07 21 and 28 and 03 83 27 16... 080904, ref SDS G5 5B6J
101034 - 91. Cycle 07 21 and 28 and 04 84 28 16... 080911, ref SDS G7 5B6J
101035 - 92. Cycle 08 22 and 29 and 01 85 29 17... 080918, ref SDS H1 5B6J
101036 - 93. Cycle 08 22 and 29 and 02 86 30 18... 080925, ref SDS H4 5B6J
101037 - 94. Cycle 08 22 and 29 and 03 87 31 19... 081002, ref SDS 0 5B6J
101039 - ..
101040 - Today is the 3rd treatment of the 8th cycle with cetuximab and
101041 - Carboplatin together. This is the 31st treatment overall with
101042 - cetuximab on the 2nd arm of the clinical study, but is only the 19th
101043 - treatment with Carboplatin due to low blood counts.
101044 -
101045 - [On 081004 Millie does not feel well; may be side effects of
101046 - Neupogen, or from chemotherapy since symptoms do not closely
101047 - match Neupogen side effects. ref SDS H7 Y17L
101049 - ..
101050 - Catherine is out for awhile. She injured her calf muscle running, and
101051 - is now on crutches. Sounds like Catherine is following Millie's
101052 - example, injuring her knee while hiking at Lafayette reservoir 2 days
101053 - ago on 080923. ref SDS H3 FN5K
101055 - ..
101056 - Diane is the nurse today.
101057 -
101058 -
101059 -
1011 -
SUBJECTS
Default Null Subject Account for Blank Record
1703 -
170401 - ..
170402 - Schedule Weekly Treatments Continue on Thursdays
170403 -
170404 - Follow up ref SDS H4 1K7H, ref SDS H1 1K7H.
170405 -
170406 - The current schedule through 090115 is listed on 080918. ref SDS H1
170407 - PN6F
170409 - ..
170410 - The schedule for Neupogen through 081108 is listed on 080929.
170411 - ref SDS H2 SY8G
170412 -
170413 -
170414 -
170415 -
1705 -
SUBJECTS
Blood Tests Labs Infusion Clinic Evaluate Safe Chemotherapy 1st Trea
2503 -
2504 - 0750
250501 - ..
250502 - Labs Blood Test
250503 -
250504 - Follow up ref SDS H4 FW5N, ref SDS H1 FW5N.
250505 -
250506 - Adding Carboplatin to the treatment protocol now requires weekly blood
250507 - tests to determine if the immune system is strong enough for safe
250508 - chemotherapy treatment, reported on 070201, ref SDS 13 XR40, and
250509 - citing the clinical study protocol received from UCSF on 070116.
250510 - ref SDS 12 5U7Z
250512 - ..
250513 - Diane performed the blood draw as shown in the schedule received on
250514 - 080918. ref SDS H1 PN6F
250515 -
250516 -
250518 - ..
2506 -
2507 -
2508 - 1010
2509 -
250901 - During treatment, Diane submitted results of the test for the 3rd
250902 - treatment in the 8th cycle. Scope is the same as for the 3rd
250903 - treatment of cycle 7 on 080904. ref SDS G5 075H
250904 -
250919 - ..
250920 - Log#: 081002 08:10
250921 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250922 - Type Results Units Normal ACRO Type Units Normal
250923 - ..
250924 - CBC with DIFF & PLT CT CBCD
250925 - ..
250926 - WBC COUNT 4.2 x10E9/L 3.4 - 10 WBC WBC x10-3 K/uL 3.4 - 10.0
250927 - RBC COUNT L 3.80 x10E12/L 4 - 5.2 RBC RBC x10-6 M/uL 3.60 - 5.70
250928 - HEMOGLOBIN 12.9 g/dL 12 - 15.5 HGB Hemoglobin g/dL 11.5 - 15.0
250929 - HEMATOCRIT 37.8 PERCENT 36 - 46 HCT Hematocrit % 34.0 - 46.0
250930 - MCV 100 fL 80 - 100 MCV MCV fL 80.0 - 100.0
250931 - MCH 34.0 pg 26 - 34 MCH
250932 - MCHC 34.2 g/dL 31 - 36 MCHC
250933 - PLATELETS 209 x10E9/L 140 - 450 PLT Plt x10-3 K/uL 140 - 400
250934 -
250935 - Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250936 - Francisco, CA 94115
250937 - ..
250938 - (NEUTS x 1000 = ANC for Kaiser)
250939 - NEUTS 1.93 x10E9/L 1.8 - 6.8 N-A ANC 1500
250940 - Neutrophils Not Reported Neutrophils % 50 - 70
250942 - ..
250943 - LYMPHS 1.72 x10E9/L 0.9 - 2.9 L-A Lymphocytes % 20 - 50
250944 - MONOS 0.26 x10E9/L 0.2 - 0.8 M-A Monocyte % 0 - 11
250945 - EOS 0.15 x10E9/L 0 - 0.4 E-A Esoinophils % 1 - 5
250946 - BASOS 0.05 x10E9/L 0 - 0.1 B-A Basophil % 0 - 2
250948 - ..
250949 - <----------------------- U C S F -----------------------> <------------- Kaiser -------------->
250950 - Type Results Units Normal ACRO Type Units Normal
250951 - ELECTROLYTE PANEL LYTE
250952 - SODIUM L 131 mmol/L 134 - 143 NA Sodium mEq/L 137 - 145
250953 - POTASSIUM 3.9 mmol/L 3.4 - 4.9 K Potassium mEq/L 3.5 - 5.3
250954 - CHLORIDE 99 mmol/L 98 - 107 CL
250955 - CARBON DIOX TOTAL L 18 mmol/L 23 - 32 CO2
250956 - ANION GAP 14 3 - 14 ANGA
250957 - ..
250958 - * UREA NITROGEN mg/dL 8 - 23 BUN BUN mg/dL 7 - 17
250959 - * GLUCOSE mg/dL 70 - 199 GLU Glucose mg/dL ? - ?
250960 - * AST U/L 16 - 41 AST AST (SGOT) U/L 14 - 36
250961 - * ALT U/L 11 - 54 ALT ALT (SGPT) U/L 11 - 66
250962 - * BILIRUBIN, TOTAL mg/dL 0.3 - 1.3 BILT Bili Total mg/dL 0.2 - 1.3
250963 - * ALKALINE PHOSPHATASE U/L 29 - 111 ALKP Alkaline Ph U/L 38 - 126
250964 - ..
250965 - * PROTEIN, TOTAL g/dL 5.8 - 8.0 TP Protine Total g/dL 6.3 - 8.2
250966 - * ALBUMIN g/dL 3.4 - 4.7 ALB Albumin g/dL 3.4 - 4.8
250967 - CALCIUM L 8.4 mg/dL 8.7 - 10.1 CA Calcium mg/dL 8.4 - 10.2
250968 - ..
250969 - MAGNESIUM 1.8 mg/dL 1.8 - 2.3 MG Magnesium mg/dL 1.6 - 2.3
250971 - ..
250972 - CREAT with eGFR
250973 - CREATININE 0.56 mg/dL 0.42 - 1.06 CR Creatinine mg/dL 0.6 - 1.2
250974 -
250975 - Note: Creatinine assay changed to IDMS standardization on
250976 - February 4, 2008 causing decrease in results of approximately
250977 - 0.09 mg/dL
250979 - ..
250980 - eGFR if Caucasian >60 mL/min GFRC
250981 - eGFR if African Amer >60 mL/min GFRA
250982 -
250983 - eGFR corrected for 1.73 sq meters of body surface area
250984 - Note: eGFR is only an estimation. Please see online Lab Manual
250985 - for potential limitations.
250986 - Performed at Mt Zion Clin Lab, 1600 Divisadero, San Francisco,
250987 - CA 94115
250989 - ..
250990 - * Labs today included following tests previously omitted...
250991 -
250992 - GLUCOSE.............................. ref SDS 0 SE9J
250993 - ALBUMIN
250994 - PROTEIN, TOTAL....................... ref SDS 0 GT9I
250996 - ..
250997 - Labs on 080925 omitted following tests...
250998 -
250999 - PROTEIN, TOTAL....................... ref SDS H4 GT9I
251001 - ..
251002 - Labs on 080918 included tests previously omitted...
251003 -
251004 - GLUCOSE.............................. ref SDS H1 SE9J
251005 - PROTEIN, TOTAL....................... ref SDS H1 GT9I
251006 - ALBUMIN
251008 - ..
251009 - Labs on 080821 omitted following tests...
251010 -
251011 - GLUCOSE.............................. ref SDS F6 SE9J
251012 - ALBUMIN.............................. ref SDS F6 GT9I
251013 - PROTEIN, TOTAL
251015 - ..
251016 - Labs on 080726 omitted following tests...
251017 -
251018 - GLUCOSE.............................. ref SDS D8 SE9J
251019 - ALBUMIN.............................. ref SDS D8 GT9I
251021 - ..
251022 - Labs on 080626 omitted following tests...
251023 -
251024 - GLUCOSE.............................. ref SDS B7 HS7I
251025 - PROTEIN, TOTAL
251026 - ALBUMIN
251027 - CALCIUM
251029 - ..
251030 - Case study on 080626 shows these four tests, which have been omitted
251031 - and included in various combinations the past 4 cycles, where
251032 - consistently included for the prevous 15 cycles. ref SDS B7 HS8F
251033 -
251034 -
2511 -
SUBJECTS
Absolute Neutrophils Count ANC 6850 Above 1500 NEUTS 6.85 Above 1.5
3403 -
340401 - ..
340402 - NEUTS 1.93 Increase 2nd Week Chemotherapy Received
340403 - Chemotherapy Received Blood Counts Rise Significantly
340404 - Blood Counts Rise Significantly Chemotherapy Carboplatin Received
340405 -
340406 - Follow up ref SDS H4 PU6K, ref SDS H1 PU6K.
340407 -
340408 - Blood counts decreased this week, shown by the Lab report today with
340409 - NEUTS 1.93, ref SDS 0 QY6H, compared with NEUTS 3.82 last week on
340410 - 080925, ref SDS H4 QY6H This is still well above UCSF standard of 1.5
340411 - for Millie to safely get chemotherapy treatment. Since today is the
340412 - 3rd week in the new cycle, Millie had 2 Neupogen treatments last week
340413 - at Kaiser, reported on 080927, ref SDS H5 UZ7K, and according to the
340414 - schedule on 080920. ref SDS H2 SY8G
340416 - ..
340417 - Neutropenia has caused a "roller coaster" above and below specified
340418 - target from week to week, while getting Neupogen treatments in recent
340419 - months; today seems to show possible lessening of neutropenia with
340420 - blood counts rising several weeks in a row, shown in case study below.
340421 - ref SDS 0 OK67
340423 - ..
340424 - Patient history getting cetuximab and Carboplatin is listed above.
340425 - ref SDS 0 5B6J
340427 - ..
340428 - Side effects of Neupogen is listed below. ref SDS 0 SB8I
340430 - ..
340431 - Fitness from hiking is listed in case study on 080930. ref SDS H6 8G5M
340432 -
340433 -
340434 -
340435 -
3405 -
SUBJECTS
Default Null Subject Account for Blank Record
3503 -
350401 - ..
350402 - Neupogen Case Study Missed Carboplatin Treatments Low Blood Counts
350403 -
350404 - Follow up ref SDS H4 EP7N, ref SDS H1 EP7N.
350405 -
350406 - Case study on 060809 shows Millie has often received chemotherapy when
350407 - blood counts are below the standard for safe treatments, and on some
350408 - occassions has received Neupogen to increase blood counts. ref SDS 7
350409 - HV45
350411 - ..
350412 - Research on neutropenia was reported on 070301, ref SDS 17 O59H, when
350413 - Doctor Rugo was concerned about holding blood counts with weekly
350414 - Carboplatin treatments. ref SDS 17 VF6O
350416 - ..
350417 - Millie has received 34 Neupogen treatments, and missed 4 chemotherapy
350418 - treatments due to rising neutropenia. Millie's letter to the medical
350419 - team on 080307 asked about solving low blood counts. ref SDS 83 HS6R
350420 - On 080423 Millie notified the medical team to maintain a full dose of
350421 - Carboplatin because these treatments yielded favorable response.
350422 - ref SDS 93 TY6Y On 080501 a mixup in communication reduced the dose
350423 - of Carboplatin with the aim of not missing treatments. Adding
350424 - Neupogen to avoid missing treatments might have enabled maintaining
350425 - full dose of Carboplatin to increase recovery. ref SDS 97 CZ3N
350427 - ..
350428 - Consideration last week on 080925 to skip Neupogen treatments next
350429 - week, if blood counts remain high, ref SDS H4 5U5F, might be modified
350430 - this week by getting only 1 Neupogen treatment.
350432 - ..
350433 - Fitness from hiking is listed in case study on 080930. ref SDS H6 8G5M
350435 - ..
350436 - Ability to maintain blood counts reported today, enables steady
350437 - chemotherapy treatments. This may relate to stabilizing cancer marker
350438 - CA 15-3 95 on 080918. ref SDS H1 VK6H Millie has received only 19 of
350439 - 23 total treatments prescribed with Carboplatin, since starting the
350440 - 2nd arm of the clinical study on 080306...
350442 - ..
350443 - Neupogen Carboplatin
350444 - Date NEUTS Cur Totl Cycl Trm Rcvd Missed
350445 -
350446 - 081002 1.93 2 36 8 3 19.......... ref SDS 0 QY6H
350447 - 080925 3.82 2 34 8 2 18.......... ref SDS H4 QY6H
350448 - 080918 2.07 2 32 8 1 17.......... ref SDS H1 QY6H
350449 - 080911 1.43 2 30 7 4 16.......... ref SDS G7 QY6H
350450 - 080904 1.99 2 28 7 3 16.......... ref SDS G5 QY6H
350451 - 080828 3.09 2 26 7 2 15.......... ref SDS G4 QY6H
350452 - 080821 0.99 2 24 7 1 14 4... ref SDS F6 QY6H
350453 - 080814 1.37 0 22 6 4 14.......... ref SDS F4 QY6H
350454 - 080807 2.41 2 22 6 3 14.......... ref SDS E8 QY6H
350455 - 080731 1.92 2 20 6 2 13.......... ref SDS E2 QY6H
350456 - 080724 2.32 2 18 6 1 12.......... ref SDS D8 QY6H
350457 - 080717 2.47 1 16 5 4 11.......... ref SDS D1 QY6H
350458 - 080710 5.12 2 15 5 3 11.......... ref SDS C5 QY6H
350459 - 080703 2.90 2 13 5 2 10.......... ref SDS C2 QY6H
350460 - 080626 1.80 2 11 5 1 09.......... ref SDS B7 QY6H
350461 - 080619 0.74 1 9 4 4 08.......... ref SDS B2 QY6H
350462 - 080612 3.77 2 8 4 3 08.......... ref SDS A9 QY6H
350463 - 080605 1.55 2 6 4 2 07.......... ref SDS A6 QY6H
350464 - 080529 2.26 1 4 4 1 06.......... ref SDS A5 QY6H
350465 - 080522 0.96 0 3 4 05.......... ref SDS A2 QY6H
350466 - 080515 1.21 0 3 3 05 3... ref SDS A1 QY6H
350467 - 080508 5.41 1 3 3 2 05.......... ref SDS A0 QY6H
350468 - 080501 1.34 1 2 3 1 04.......... ref SDS 98 QY6H
350469 - 080424 1.34 0 2 4 03.......... ref SDS 95 QY6H
350470 - ..
350471 - 080417 0.95 0 2 3 03 2... ref SDS 92 QY6H
350472 - 080410 6.85 0 2 2 03.......... ref SDS 90 QY6H
350473 - 080403 1.34 1 1 2 1 02.......... ref SDS 87 QY6H
350474 - 080327 2.30 0 1 4 01.......... ref SDS 86 QY6H
350475 - 080320 1.28 0 1 3 01 1... ref SDS 85 QY6H
350476 - 080313 2.05 0 1 2 01.......... ref SDS 84 QY6H
350477 - 080306 1.75 0 1 1 00.......... ref SDS 82 QY6H
350478 -
350479 -
350480 -
3505 -
SUBJECTS
Default Null Subject Account for Blank Record
3603 -
360401 - ..
360402 - Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
360403 -
360404 - Follow up ref SDS H4 SB8I, ref SDS H1 SB8I.
360405 -
360406 - Research on Neupogen side effects was reported on 080629. ref SDS C1
360407 - RQ9I Previous case study on Neupogen side effects listed on 080925.
360408 - ref SDS H4 SB8I
360410 - ..
360411 - Fitness from hiking is listed in case study on 080930. ref SDS H6 8G5M
360413 - ..
360414 - Millie has not experienced Neupogen side effects for several days,
360415 - since about 080907, as reported on 080930. ref SDS H6 Y17L
360416 -
360417 - [On 081004 Millie does not feel well; may be side effects of
360418 - Neupogen, or from chemotherapy since symptoms do not closely
360419 - match Neupogen side effects. ref SDS H7 Y17L
360421 - ..
360422 - Side effects of Neupogen may be lessening, reported on...
360423 -
360424 - 081002................, ref SDS 0 Y17L
360425 - 080930................, ref SDS H6 Y17L
360426 - 080923................, ref SDS H3 K16F
360427 - 080915................, ref SDS G8 9W9I
360428 - 080810................, ref SDS F2 9W9I
360429 - 080803................, ref SDS E3 9W9I
360430 - 080726................, ref SDS E0 9W9I
360431 - 080721................, ref SDS D5 9W9I
360432 - 080713................, ref SDS C8 RM94
360433 - 080629................, ref SDS C1 6Q5J
360434 - 080628................, ref SDS B9 6Q5J
360435 -
360436 - ...suggesting increased ability to tolerate 2 Neupogen treatments per
360437 - week.
360438 -
360439 -
360440 -
360441 -
360442 -
360443 -
360444 -
360445 -
3605 -